Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE)
Abstract
Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan.
One of hepatocellular carcinoma (HCC) therapeutic modality is transarterial chemoembolization (TACE). The albumin-bilirubin (ALBI) grade is amongst the newest of prognostic scores published to predict survival. The aim of this study was to analzye the ALBI grade as a three-month survival predictor in HCC patients after initial TACE. This was a retrospective analytic observational study identifying patients that underwent initial TACE from January 2013 to December 2017 in Dr. Soetomo General Hospital, Surabaya. Data were collected before treatment and analyzed to evaluate ALBI grade as a survival predictor. Out of 134 HCC patients, the subjects consisted of 100 (74.6%) male subjects and 34 (25.4%) female subjects. There were 25 (18.7%), 98 (73.1%), dan 11 (8.2%) subjects who were classified into to ALBI 1, ALBI 2, and ALBI 3, respectively, with a median ALBI score of -2.295. The ALBI grade was significantly associated with the three-month survival variable (p = 0.01; CI 95%). Using the ROC curve, we have determined a new cut-off point. The group of ALBI score ≤ -2.27 had an odds ratio of 2.549 (CI 95% 1.232-5.273) for three-month survival. The ALBI grade was associated with three-month survival after initial TACE in patients with HCC.
| How to Cite this Article |
| Pubmed Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). SRP. 2020; 11(5): 205-208. doi:10.31838/srp.2020.5.31 Web Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). http://www.sysrevpharm.org/?mno=108415 [Access: March 29, 2021]. doi:10.31838/srp.2020.5.31 AMA (American Medical Association) Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). SRP. 2020; 11(5): 205-208. doi:10.31838/srp.2020.5.31 Vancouver/ICMJE Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). SRP. (2020), [cited March 29, 2021]; 11(5): 205-208. doi:10.31838/srp.2020.5.31 Harvard Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan (2020) Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). SRP, 11 (5), 205-208. doi:10.31838/srp.2020.5.31 Turabian Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. 2020. Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). Systematic Reviews in Pharmacy, 11 (5), 205-208. doi:10.31838/srp.2020.5.31 Chicago Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. "Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE)." Systematic Reviews in Pharmacy 11 (2020), 205-208. doi:10.31838/srp.2020.5.31 MLA (The Modern Language Association) Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan. "Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE)." Systematic Reviews in Pharmacy 11.5 (2020), 205-208. Print. doi:10.31838/srp.2020.5.31 APA (American Psychological Association) Style Ummi Maimunah, Andri Pramana Restu, Iswan Abbas Nusi, Herrry Purbayu, Titong Sugihartono, Ulfa Kholili, Budi Widodo, Muhammad Miftahussurur, Husin Thamrin, Amie Vidyani, Poernomo Boedi Setiawan (2020) Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients after Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated With TACE). Systematic Reviews in Pharmacy, 11 (5), 205-208. doi:10.31838/srp.2020.5.31 |
Abstract
PDF
How to cite this article
Related Records